Close

Tissue factor

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Tissue factor, also called platelet tissue factor, factor III, thromboplastin, or CD142 is a protein encoded by the F3 gene present in subendothelial tissue and leukocytes necessary for the initiation of thrombin formation from the zymogen prothrombin. Tissue factor (TF) is a transmembrane glycoprotein that is essential for hemostasis. It binds the coagulation serine protease factor VII/VIIa (FVII/VIIa) to form a bimolecular complex that functions as the primary initiator of coagulation in vivo. Many studies have shown that levels of circulating TF in the form of MPs are increased in various diseases, including cardiovascular disease, sepsis, diabetes, and cancer. TF is expressed by all types of cancers. Importantly, TF-dependent activation of coagulation has been implicated in cancer-associated thrombosis and metastasis.

Associated Disease
  • CAR Vector Products

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-LC288 Anti-F3 h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human XHM507 Human Protein-41BB-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.